このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Tandem Diabetes Care 将来の成長

Future 基準チェック /16

Tandem Diabetes Care利益と収益がそれぞれ年間53.7%と9.9%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に-4.7% 54.3%なると予測されています。

主要情報

53.7%

収益成長率

54.3%

EPS成長率

Medical Equipment 収益成長	17.6%
収益成長率	9.9%
将来の株主資本利益率	-4.7%
アナリストカバレッジ	Good
最終更新日	21 Jun 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

BOVESPA:T2ND34 - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	1,055	-41	63	103	11
12/31/2025	961	-75	13	66	15
12/31/2024	869	-110	-17	35	16
3/31/2024	770	-141	-67	-21	N/A
12/31/2023	748	-223	-83	-32	N/A
9/30/2023	771	-208	-49	-19	N/A
6/30/2023	790	-224	-41	5	N/A
3/31/2023	795	-204	-33	18	N/A
12/31/2022	801	-95	8	50	N/A
9/30/2022	791	-68	21	64	N/A
6/30/2022	766	-13	50	74	N/A
3/31/2022	738	6	74	96	N/A
12/31/2021	703	16	88	111	N/A
9/30/2021	661	22	85	107	N/A
6/30/2021	605	7	62	87	N/A
3/31/2021	542	-25	45	74	N/A
12/31/2020	499	-34	-8	25	N/A
9/30/2020	439	-49	-6	29	N/A
6/30/2020	410	-42	5	37	N/A
3/31/2020	394	-17	1	25	N/A
12/31/2019	362	-25	22	42	N/A
9/30/2019	330	-24	23	37	N/A
6/30/2019	282	-55	0	10	N/A
3/31/2019	223	-113	-4	0	N/A
12/31/2018	184	-123	-11	-8	N/A
9/30/2018	148	-138	-38	-34	N/A
6/30/2018	129	-119	-52	-50	N/A
3/31/2018	116	-82	-61	-58	N/A
12/31/2017	108	-73	N/A	-66	N/A
9/30/2017	96	-76	N/A	-68	N/A
6/30/2017	82	-90	N/A	-67	N/A
3/31/2017	83	-87	N/A	-66	N/A
12/31/2016	84	-83	N/A	-61	N/A
9/30/2016	84	-81	N/A	-58	N/A
6/30/2016	88	-70	N/A	-54	N/A
3/31/2016	81	-72	N/A	-59	N/A
12/31/2015	73	-72	N/A	-59	N/A
9/30/2015	62	-79	N/A	-62	N/A
6/30/2015	59	-79	N/A	-61	N/A
3/31/2015	54	-79	N/A	-60	N/A
12/31/2014	50	-80	N/A	-61	N/A
9/30/2014	42	-85	N/A	-61	N/A
6/30/2014	36	-78	N/A	-58	N/A
3/31/2014	32	-74	N/A	-56	N/A
12/31/2013	29	-63	N/A	-48	N/A
9/30/2013	21	-48	N/A	-45	N/A
6/30/2013	13	-43	N/A	-43	N/A

アナリストによる今後の成長予測

収入対貯蓄率: T2ND34今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: T2ND34今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: T2ND34今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: T2ND34の収益 ( 9.9% ) BR市場 ( 7.2% ) よりも速いペースで成長すると予測されています。

高い収益成長: T2ND34の収益 ( 9.9% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: T2ND34 3 年以内に赤字になると予測されています。

Tandem Diabetes Care 将来の成長

Future 基準チェック /16

主要情報

今後の成長に関する最新情報

Tandem Diabetes Care, Inc. Updates Sales Guidance for the Full Year of 2022

Tandem Diabetes Care, Inc. Revises Financial Guidance for the Full Year Ending December 31, 2022

Recent updates

Tandem Diabetes Care, Inc. Appoints Jean-Claude Kyrillos as Executive Vice President and Chief Operating Officer, Effective June 21, 2024

Tandem Diabetes Care, Inc. to Report Q1, 2024 Results on May 02, 2024

Tandem Diabetes Care Launches Tandem Mobi, the World’s Smallest, Durable Automated Insulin Delivery System

Tandem Diabetes Care, Inc. to Report Q4, 2023 Results on Feb 21, 2024

Tandem Diabetes Care, Inc. Announces Full U.S. Launch of Tandem Source, a New Diabetes Management Platform for Customers and Healthcare Providers

Tandem Diabetes Care, Inc. Launches T:Slim X2 Insulin Pump Software with Dexcom G7 CGM Integration in U.S

Tandem Diabetes Care, Inc. Appoints Mark Novara as Executive Vice President and Chief Commercial Officer, Effective November 13, 2023

Tandem Diabetes Care, Inc. to Report Q3, 2023 Results on Nov 01, 2023

Holzer & Holzer, LLC Files Class Action Lawsuit Filed on Behalf of Tandem Diabetes Care, Inc

Tandem Diabetes Care, Inc. Announces the Resignation of Brian B. Hansen as Executive Vice President and Chief Commercial Officer, Effective December 31, 2023

Tandem Diabetes Care, Inc. Receives U.S. FDA Clearance

Tandem Diabetes Care, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Tandem Diabetes Care, Inc. (NasdaqGM:TNDM) completed the acquisition of AMF Medical SA .

Tandem Diabetes Care, Inc. to Report Q4, 2022 Results on Feb 22, 2023

Tandem Diabetes Care, Inc. (NasdaqGM:TNDM) entered into a definitive agreement to acquire AMF Medical SA for CHF million.

Tandem Diabetes Care, Inc. (NasdaqGM:TNDM) entered into a definitive agreement to acquire AMF Medical SA for CHF million.

Tandem Diabetes Care, Inc. Study Demonstrates Improvements of All Clinical Endpoints in Adults with Type 2 Diabetes Using Control-IQ Technology

Tandem Diabetes Care, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Tandem Diabetes Care Achieves Milestone of 1 Million Insulin Boluses Delivered Using Its t:Connect Mobile App

Tandem Diabetes Care, Inc. Updates Sales Guidance for the Full Year of 2022

Tandem Diabetes Care, Inc. (NasdaqGM:TNDM) acquired Capillary Biomedical, Inc.

Tandem Diabetes Care, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Tandem Diabetes Care Reports the Appointments of Myoung Cha and Joao Malagueira as Independent Members of Its Board of Directors, as of June 15, 2022

Tandem Diabetes Care, Inc. Appoints Myoung Cha and Joao Malagueira as Independent Members of its Board of Directors

Tandem Diabetes Care, Inc. Revises Financial Guidance for the Full Year Ending December 31, 2022

Tandem Diabetes Care, Inc., Annual General Meeting, May 25, 2022

Tandem Diabetes Care, Inc. to Report Q1, 2022 Results on May 04, 2022

Tandem Diabetes Care, Inc. Appoints David B. Berger as Executive Vice President, Chief Operating Officer and Assistant Secretary

Tandem Diabetes Care, Inc. Announces FDA Clearance for the t:slim X2 Insulin Pump to Bolus Using the t:connect Mobile App

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘